The American pharmaceutical company Pfizer has agreed with the Russian company Pharmstandard on the production of four drugs for the treatment of cancer at the Pharmstandard-UfaVITA plant. The press service of the concern noted that they are going to produce drugs for lung, kidney, breast cancer and chronic myeloid leukemia. The company is likely to produce approximately two million tablets a year.
Pharmstandard-UfaVITA will provide the partner with product development services. The first commercial series is expected to be released in 2024. Within the framework of the project, it is planned to localize the production of a full cycle of four innovative drugs in eight dosages, all of them are included in the list of vital and essential drugs,”the Pharmstandard press service said.
The contract participants reported that the drugs were selected based on the needs of cancer patients in Russia. According to preliminary data, the plant will produce approximately two million tablets and capsules per year. The Russian company expressed the hope that cooperation with Pfizer will expand patients' access to the treatment they need.
Pfizer CEO in Russia and Belarus Eric Patruillard stressed that the agreement was signed in order to develop the company's investment strategy in Russia.
“We are confident that thanks to our partnership, we will be able to meet the demand of Russian patients for drugs for the therapy of oncology, which remains one of the most pressing healthcare problems in Russia,” he added.
In November, Pfizer said it did not rule out the registration in Russia of its BNT162b2 vaccine, which has shown 90% effectiveness in preventing coronavirus disease. In response to a request from the Daily Storm, company representatives emphasized that they are ready to cooperate with the authorities of states around the world to disseminate their development.
The agreement signed with the Russian concern does not include the production of a vaccine against COVID-19 in Ufa.
In September, the American company Gilead Sciences and Pharmstandard signed an agreement to establish the supply and localization of the Vekluri drug for the treatment of COVID-19 in Russia.
Pfizer has partnered with the German company BioNTech to develop a coronavirus vaccine. In early November, they announced a successful third phase of clinical trials of the drug. Pfizer later announced that the drug was 95% effective. The American concern has already announced plans to launch the production of the drug in the United States and Europe, and in the future, the Americans want to establish a conveyor belt in other countries. The company intends to sell its product on commercial terms.
]>
